Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Deborah J. Wong(University of California, Los Angeles), Antoni Ribas(University of California, Los Angeles)
Cited by 123
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
|New England Journal of Medicine|2016|3.1k
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
|Nature|2010|2.5k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
|Cell Reports|2017|1.9k